Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David T Teachey

Showing results (41-50 of 214) with videos related to

Pageof 22
Sort By:
Seminars in Immunopathology|July 16, 2024
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapyAndrew D Hughes, David T Teachey, Caroline Diorio
Blood|October 2, 2024
Classification and risk stratification in T-lineage acute lymphoblastic leukemiaPetri Pölönen, Charles G Mullighan, David T Teachey
Blood Cancer Discovery|April 9, 2026
Genomic Insights into the Biology of T-lineage Acute Lymphoblastic LeukemiaPetri Pölönen, David T Teachey, Charles G Mullighan
Immunological Reviews|July 30, 2019
Cellular therapy: Immune-related complicationsJoseph H Oved, David M Barrett, David T Teachey
Blood|September 3, 2020
Optimizing therapy in the modern age: differences in length of maintenance therapy in acute lymphoblastic leukemiaDavid T Teachey, Stephen P Hunger, Mignon L Loh
Blood|February 16, 2024
How I treat ETP-ALL in childrenRyan J Summers, David T Teachey, Stephen P Hunger
Current Opinion in Pediatrics|December 24, 2013
Toxicity management for patients receiving novel T-cell engaging therapiesDavid M Barrett, David T Teachey, Stephan A Grupp
British Journal of Haematology|April 7, 2009
Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignanciesDavid T Teachey, Stephan A Grupp, Valerie I Brown
British Journal of Haematology|November 26, 2009
Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS)David T Teachey, Alix E Seif, Stephan A Grupp
Frontiers in Oncology|June 7, 2014
Targeting the PI3K/mTOR Pathway in Pediatric Hematologic MalignanciesSarah K Tasian, David T Teachey, Susan R Rheingold
Pageof 22

Showing results (41-50 of 214) with videos related to

Sort By:
Pageof 22
Seminars in Immunopathology|July 16, 2024
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapyAndrew D Hughes, David T Teachey, Caroline Diorio
Blood|October 2, 2024
Classification and risk stratification in T-lineage acute lymphoblastic leukemiaPetri Pölönen, Charles G Mullighan, David T Teachey
Blood Cancer Discovery|April 9, 2026
Genomic Insights into the Biology of T-lineage Acute Lymphoblastic LeukemiaPetri Pölönen, David T Teachey, Charles G Mullighan
Immunological Reviews|July 30, 2019
Cellular therapy: Immune-related complicationsJoseph H Oved, David M Barrett, David T Teachey
Blood|September 3, 2020
Optimizing therapy in the modern age: differences in length of maintenance therapy in acute lymphoblastic leukemiaDavid T Teachey, Stephen P Hunger, Mignon L Loh
Blood|February 16, 2024
How I treat ETP-ALL in childrenRyan J Summers, David T Teachey, Stephen P Hunger
Current Opinion in Pediatrics|December 24, 2013
Toxicity management for patients receiving novel T-cell engaging therapiesDavid M Barrett, David T Teachey, Stephan A Grupp
British Journal of Haematology|April 7, 2009
Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignanciesDavid T Teachey, Stephan A Grupp, Valerie I Brown
British Journal of Haematology|November 26, 2009
Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS)David T Teachey, Alix E Seif, Stephan A Grupp
Frontiers in Oncology|June 7, 2014
Targeting the PI3K/mTOR Pathway in Pediatric Hematologic MalignanciesSarah K Tasian, David T Teachey, Susan R Rheingold
Pageof 22